GenSight Biologics S.A. (GSGTF)
USD 0.32
(0.0%)
USD 0.32
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 18.42 Million EUR | 36.15% |
| 2022 | 13.53 Million USD | -5.23% |
| 2021 | 14.28 Million USD | -19.22% |
| 2020 | 17.68 Million USD | 118.82% |
| 2019 | 8.07 Million USD | 134.81% |
| 2018 | 3.44 Million EUR | 13.45% |
| 2017 | 3.03 Million EUR | 3.8% |
| 2016 | 2.92 Million EUR | 369.63% |
| 2015 | 622.19 Thousand EUR | -1.6% |
| 2014 | 632.33 Thousand EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q1 | 20.83 Million EUR | 64.74% |
| 2023 Q3 | 22.76 Million EUR | 30.09% |
| 2023 FY | 18.42 Million EUR | 36.15% |
| 2023 Q4 | 18.42 Million EUR | -19.03% |
| 2023 Q2 | 17.49 Million USD | -16.03% |
| 2022 Q3 | 16.96 Million EUR | 46.97% |
| 2022 FY | 13.53 Million USD | -5.23% |
| 2022 Q1 | 15.2 Million EUR | 20.98% |
| 2022 Q2 | 11.54 Million EUR | -24.06% |
| 2022 Q4 | 12.64 Million EUR | -25.46% |
| 2021 Q3 | 16.77 Million EUR | 19.53% |
| 2021 Q4 | 12.56 Million EUR | -25.07% |
| 2021 Q2 | 14.03 Million EUR | -23.11% |
| 2021 FY | 14.28 Million USD | -19.22% |
| 2021 Q1 | 18.24 Million EUR | 26.28% |
| 2020 FY | 17.68 Million USD | 118.82% |
| 2020 Q4 | 14.45 Million EUR | -22.18% |
| 2020 Q3 | 18.56 Million EUR | 51.03% |
| 2020 Q2 | 12.29 Million EUR | -20.39% |
| 2020 Q1 | 15.44 Million EUR | 114.57% |
| 2019 Q4 | 7.19 Million EUR | -29.9% |
| 2019 Q1 | 6.88 Million EUR | 100.03% |
| 2019 Q2 | 4.08 Million EUR | -40.71% |
| 2019 Q3 | 10.26 Million EUR | 151.6% |
| 2019 FY | 8.07 Million USD | 134.81% |
| 2018 Q1 | 3.4 Million EUR | 12.33% |
| 2018 Q4 | 3.44 Million EUR | 0.0% |
| 2018 FY | 3.44 Million EUR | 13.45% |
| 2018 Q3 | 3.44 Million EUR | 1.0% |
| 2018 Q2 | 3.4 Million EUR | 0.0% |
| 2017 Q3 | 3.03 Million EUR | 12.29% |
| 2017 Q2 | 2.7 Million EUR | 0.0% |
| 2017 Q1 | 2.7 Million EUR | -7.56% |
| 2017 FY | 3.03 Million EUR | 3.8% |
| 2017 Q4 | 3.03 Million EUR | 0.0% |
| 2016 Q3 | 2.92 Million EUR | 0.0% |
| 2016 Q4 | 2.92 Million EUR | 0.0% |
| 2016 Q1 | - EUR | -100.0% |
| 2016 FY | 2.92 Million EUR | 369.63% |
| 2015 FY | 622.19 Thousand EUR | -1.6% |
| 2015 Q3 | 622.19 Thousand EUR | -2.09% |
| 2015 Q4 | 622.19 Thousand EUR | 0.0% |
| 2015 Q2 | 635.49 Thousand EUR | 0.0% |
| 2015 Q1 | 635.49 Thousand EUR | 0.5% |
| 2014 Q4 | 632.33 Thousand EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 FY | 632.33 Thousand EUR | 0.0% |
| 2014 Q3 | 632.33 Thousand EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -1174.131% |
| CSL Limited | 12.18 Billion USD | 99.849% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 55.275% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -347.069% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -4485.802% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 57.513% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 38.093% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -1843.326% |
| Mesoblast Limited | 118.7 Million USD | 84.475% |
| Marizyme, Inc. | 18.71 Million USD | 1.547% |
| Genus plc | 233.1 Million USD | 92.094% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -528.859% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1271.555% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -2357.067% |
| ContraFect Corporation | 2.88 Million USD | -539.639% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -13501.305% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 28.88 Million USD | 36.2% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -225.678% |
| MultiCell Technologies, Inc. | 202.58 USD | -9096553.174% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 67.945% |
| EV Biologics, Inc. | 1.49 Million USD | -1132.847% |
| Q BioMed Inc. | 4.1 Million USD | -348.372% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 44.328% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1400.21% |
| Biomind Labs Inc. | 735.54 Thousand USD | -2405.363% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -41.787% |
| Skye Bioscience, Inc. | 4.61 Million USD | -299.284% |
| SQZ Biotechnologies Company | 27.47 Million USD | 32.918% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -12921.665% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -213.877% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -692.277% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -71551.308% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -2824.722% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 89.258% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -1975.076% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -715.983% |
| GB Sciences, Inc. | 1.75 Million USD | -947.458% |
| Alpha Cognition Inc. | 1.22 Million USD | -1410.031% |
| argenx SE | 20 Million USD | 7.86% |
| HST Global, Inc. | 98.31 Thousand USD | -18643.071% |
| Halberd Corporation | 150 Thousand USD | -12185.333% |
| Enzolytics Inc. | 996.33 Thousand USD | -1749.573% |
| Resverlogix Corp. | 6.49 Million USD | -183.901% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -7109.928% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 59.552% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 72.757% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -508.95% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -160.547% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -5023.016% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -580.326% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| ONE Bio Corp. | 19.71 Million USD | 6.528% |
| Zenith Capital Corp. | 10.22 Thousand USD | -180124.939% |
| Genscript Biotech Corporation | 417.73 Million USD | 95.589% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -9085.708% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -668.562% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -7936.949% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -12296.572% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -7309.135% |
| Agentix Corp. | 50 Thousand USD | -36756.0% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 891.22 Thousand USD | -1967.713% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 9.347% |
| BioStem Technologies, Inc. | 4.71 Million USD | -291.135% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -7265.838% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 33.6 Thousand USD | -54735.446% |
| Cell Source, Inc. | 9.25 Million USD | -99.132% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -2336.909% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -2336.909% |
| NovAccess Global Inc. | 2.19 Million USD | -737.682% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -7969.114% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -8634.684% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -269.817% |
| CytoDyn Inc. | 30.07 Million USD | 38.729% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -5137.504% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -135.653% |
| SYBLEU INC | 477.5 Thousand USD | -3759.267% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -14943.265% |
| Rebus Holdings, Inc. | 310 Thousand USD | -5844.516% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -289.164% |
| Mobile Lads Corp. | 484.28 Thousand USD | -3705.205% |
| International Stem Cell Corporation | 4.17 Million USD | -341.072% |
| Bioxytran, Inc. | 1.92 Million USD | -857.299% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -29425.9% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -744.972% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -121.597% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -114.653% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -1084.715% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -6776.119% |
| Neutra Corp. | 54.15 Thousand USD | -33927.624% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -906.995% |
| PureTech Health plc | 25.51 Million USD | 27.767% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -1405.278% |
| IXICO plc | 472.02 Thousand USD | -3804.047% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -18.883% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 70.403% |
| CSL Limited | 12.18 Billion USD | 99.849% |
| Cellectis S.A. | 92.77 Million USD | 80.137% |